inclusion criteria: 1. patients ≥18 years of age, who have a clinical presentation suggestive of covid-19, or who have had a molecular laboratory assay that confirms sars-cov-2 infection that was collected prior to the first dose of study treatment. 2. patients with mild to moderate covid-19 who need admission and may require oxygen at admission but not yet requiring escalation of oxygen therapy to cpap, high flow nasal oxygen or intubation. we will not include patients with laboratory confirmation of sars-cov-2 who report no symptoms at all. 3. able to provide own consent 4. willing to have hiv test - unless already has clinical documentation of hiv infection (as evidenced by a hiv rapid test result during the admission, or any one of the following: a positive hiv elisa assay; an art prescription; a pill container for art with the patient's name; a hard copy or an electronic viral load result that includes the patient's name showing detectable hiv copies; clinical documentation of hiv sero-positivity included in the medical record) 5. randomisation must occur within 48 hours of first covid-19 diagnosis during the current illness.

inclusion criteria: 1. patients ≥18 years of age, who have a clinical presentation suggestive of covid-19, or who have had a molecular laboratory assay that confirms sars-cov-2 infection that was collected prior to the first dose of study treatment. 2. patients with mild to moderate covid-19 who need admission and may require oxygen at admission but not yet requiring escalation of oxygen therapy to cpap, high flow nasal oxygen or intubation. we will not include patients with laboratory confirmation of sars-cov-2 who report no symptoms at all. 3. able to provide own consent 4. willing to have hiv test - unless already has clinical documentation of hiv infection (as evidenced by a hiv rapid test result during the admission, or any one of the following: a positive hiv elisa assay; an art prescription; a pill container for art with the patient's name; a hard copy or an electronic viral load result that includes the patient's name showing detectable hiv copies; clinical documentation of hiv sero-positivity included in the medical record) 5. randomisation must occur within 48 hours of first covid-19 diagnosis during the current illness.

inclusion criteria: patients ≥18 years of age, who have a clinical presentation suggestive of covid-19, or who have had a molecular laboratory assay that confirms sars-cov-2 infection that was collected prior to the first dose of study treatment. patients with mild to moderate covid-19 who need admission and may require oxygen at admission but not yet requiring escalation of oxygen therapy to cpap, high flow nasal oxygen or intubation. we will not include patients with laboratory confirmation of sars-cov-2 who report no symptoms at all. able to provide own consent willing to have hiv test - unless already has clinical documentation of hiv infection (as evidenced by a hiv rapid test result during the admission, or any one of the following: a positive hiv elisa assay; an art prescription; a pill container for art with the patient's name; a hard copy or an electronic viral load result that includes the patient's name showing detectable hiv copies; clinical documentation of hiv sero-positivity included in the medical record) randomisation must occur within 48 hours of first covid-19 diagnosis during the current illness.

inclusion criteria: patients ≥18 years of age, who have a clinical presentation suggestive of covid-19, or who have had a molecular laboratory assay that confirms sars-cov-2 infection that was collected prior to the first dose of study treatment. patients with mild to moderate covid-19 who need admission and may require oxygen at admission but not yet requiring escalation of oxygen therapy to cpap, high flow nasal oxygen or intubation. we will not include patients with laboratory confirmation of sars-cov-2 who report no symptoms at all. able to provide own consent willing to have hiv test - unless already has clinical documentation of hiv infection (as evidenced by a hiv rapid test result during the admission, or any one of the following: a positive hiv elisa assay; an art prescription; a pill container for art with the patient's name; a hard copy or an electronic viral load result that includes the patient's name showing detectable hiv copies; clinical documentation of hiv sero-positivity included in the medical record) randomisation must occur within 48 hours of first covid-19 diagnosis during the current illness.

inclusion criteria: 1. patients ≥18 years of age, who have a clinical presentation suggestive of covid-19, or who have had a molecular laboratory assay that confirms sars-cov-2 infection that was collected prior to the first dose of study treatment. 2. patients with mild to moderate covid-19 who need admission and may require oxygen at admission but not yet requiring escalation of oxygen therapy to cpap, high flow nasal oxygen or intubation. we will not include patients with laboratory confirmation of sars-cov-2 who report no symptoms at all. 3. able to provide own consent 4. willing to have hiv test - unless already has clinical documentation of hiv infection (as evidenced by a hiv rapid test result during the admission, or any one of the following: a positive hiv elisa assay; an art prescription; a pill container for art with the patient's name; a hard copy or an electronic viral load result that includes the patient's name showing detectable hiv copies; clinical documentation of hiv sero-positivity included in the medical record) 5. randomisation must occur within 48 hours of first covid-19 diagnosis during the current illness.

inclusion criteria: 1. patients ≥18 years of age, who have a clinical presentation suggestive of covid-19, or who have had a molecular laboratory assay that confirms sars-cov-2 infection that was collected prior to the first dose of study treatment. 2. patients with mild to moderate covid-19 who need admission and may require oxygen at admission but not yet requiring escalation of oxygen therapy to cpap, high flow nasal oxygen or intubation. we will not include patients with laboratory confirmation of sars-cov-2 who report no symptoms at all. 3. able to provide own consent 4. willing to have hiv test - unless already has clinical documentation of hiv infection (as evidenced by a hiv rapid test result during the admission, or any one of the following: a positive hiv elisa assay; an art prescription; a pill container for art with the patient's name; a hard copy or an electronic viral load result that includes the patient's name showing detectable hiv copies; clinical documentation of hiv sero-positivity included in the medical record) 5. randomisation must occur within 48 hours of first covid-19 diagnosis during the current illness.